SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 1, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago
Insider cluster: 2 insiders, $125K total
Actionable Insight • Neutral

Insider sales are too small to warrant concern. Monitor for any larger insider transactions in the coming weeks, particularly if accompanied by material news. The earnings release itself is the more relevant event for traders.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.77
T+0 close · Apr 30, 2026 · via day close
Latest settled
+4.88%
T+60 · $25.98
Vs SPY
+1.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $24.77entry
  2. T+1 · 7mo ago +0.16%α +0.50% · $24.81
  3. T+5 · 6mo ago +5.49%α +3.14% · $26.13
  4. T+20 · 6mo ago −7.75%α −13.04% · $22.85
  5. T+60 · 4mo ago +4.88%α +1.82% · $25.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Ultragenyx insiders (CFO and Chief Medical Officer) sold a combined $125K in open-market transactions over the past week, representing just 0.005% of market cap. The sales followed the company's earnings release and are negligible relative to company size, indicating routine portfolio management rather than a negative signal.

Key Financial Metrics

Direction
selling
Total Value
$125.2K
Insiders
2

Key Facts

  • CFO Howard Horn sold 4,683 shares at ~$24.90 for $117K on May 1.
  • Chief Medical Officer Eric Crombez sold 344 shares at $24.96 for $9K on May 5.
  • Total insider sales of $125K represent 0.005% of RARE's $2.5B market cap.
  • Sales occurred within one day of the company's May 5 earnings release (8-K Item 2.02).

Financial Impact

Trivial insider selling of $125K total, immaterial to company valuation.

Risk Factors

  • No material risk from these sales; however, continued insider selling at larger volumes could signal management sentiment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RARE-1778093500730

Track record

22 reports on RARE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
  3. Nov 3, 202613d ago 8-K Mixed 6/10 No price data
  4. Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
  6. Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
  7. Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
  8. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
  9. Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
  10. Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 7h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026